BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Monday, March 18, 2024
Home
»
Newsletters
» BioWorld Asia
BioWorld Asia
May 22, 2002
View Archived Issues
European Parliament Endorses Part Of Biotech Spending Plan
Read More
Rational Drug Discovery Approach Looks Promising For Alzheimer's
Read More
Genome Express Offers Bacterial Genomics Sequencing Service
Read More
Speedel Moves SPP 301 Into Phase II Pilot Studies
Read More
Celltech Picks Amgen To Help Advance Osteoporosis Program
Read More
HGS Gets Exclusive Development Rights To CAT Cancer Antibody
Read More
CeNeS Releases Positive Interim Results Of CNS5161 In Phase II
Read More
Enact Acquires Rights To Cytoxic, Prepares To File For Approvals
Read More
Other News To Note
Read More
Genset Chairman Resigns, Is Succeeded By Vasseur
Read More
Australian States Compete In Separate Biotech Initiatives
Read More
IDM Receives Approval For Ovarian Cancer Therapy Trial
Read More
Ark Delays Initial Public Offering Due To Unfavorable Conditions
LONDON - Ark Therapeutics Group plc postponed its initial public offering on the London Stock Market, blaming "unusually adverse market conditions." (BioWorld International)
Read More